Letter--Prudent Formulary Management or Underutilization of the Novel P2Y12 Receptor Inhibitors in Patients with Acute Coronary Syndrome Who Received Percutaneous Coronary Intervention?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 28448773.
- Also identified by DOI 10.18553/jmcp.2017.23.5.598 and PMC identifier 10398319.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The author is a former employee of AstraZeneca and owns stock in AstraZeneca. The author reports no conflicts of interest related to the subject of this letter.
Medical subject headings
- Acute Coronary Syndrome
- Percutaneous Coronary Intervention